Transdermal nitroglycerin as a step 3 antihypertensive drug

Geza Simon, Virginia J. Wittig, Jay N Cohn

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


The antihypertensive effect of transdermal nitroglycerin was tested in 11 men with hypertension (mean age 60 years) whose diastolic blood pressure exceeded 90 mm Hg while receiving a diuretic and a (β-adrenergic blocker. In a double-blind, randomized crossover trial the subjects received weekly increments of placebo or nitroglycerin (5, 10, 20, and 30 cm2) for 4 weeks each. The final dose of nitroglycerin was 22.5 cm2 (mean). During week 4 of nitroglycerin dosing, sitting and standing systolic blood pressures were reduced (P < 0.05). Diastolic blood pressures and heart rates did not change during the study. In the five subjects with systolic hypertension (%150 mm Hg), the mean reduction in systolic blood pressure was 24 mm Hg (P < 0.01). Further studies are needed to determine if transdermal nitroglycerin has a role in the treatment of systolic hypertension. (Clin Pharmacol Ther 1986;40:42-5.).

Original languageEnglish (US)
Pages (from-to)42-45
Number of pages4
JournalClinical pharmacology and therapeutics
Issue number1
StatePublished - Jul 1986


Dive into the research topics of 'Transdermal nitroglycerin as a step 3 antihypertensive drug'. Together they form a unique fingerprint.

Cite this